Latest Asx Listings News

Sky Metals Ltd has confirmed its recent trading halt was requested pending a material capital raising announcement, affirming compliance with ASX disclosure rules.

FSA Group Limited has announced an on-market buy-back program targeting up to 12.5 million ordinary shares, signaling a strategic move to optimise its capital structure over the next 10 months.

Weebit Nano has responded to an ASX price query following a sharp rise in its share price and trading volume, attributing the activity to a misleading article on the Motley Fool website. The company denies any undisclosed price-sensitive information and confirms full compliance with ASX disclosure rules.

Orbminco Limited is proposing a 20 – 1 consolidation of its issued shares to streamline its capital structure and broaden investor appeal, with shareholder approval sought in September.

Ausmon Resources has addressed a recent spike in its share price and trading volume, attributing the market interest to prior drilling assay results for rare earth elements in South Australia.

iTech Minerals has confirmed it will soon announce new high-grade antimony findings at its Reynold Range Project, following a notable uptick in its share price and trading volume.

Andromeda Metals has addressed recent share price gains and trading volume spikes, attributing the activity to ongoing funding efforts and strategic project studies rather than undisclosed information.

Tombador Iron Limited is set to transform itself by acquiring GoviEx Uranium, creating a new ASX-listed uranium company focused on Zambia’s Muntanga Project. This deal includes a significant capital raise and board overhaul, aiming for a November 2025 completion.

Challenger Limited reported a robust FY25 with a 9% rise in normalised profit and a strategic push into digital transformation and retirement income solutions.

Challenger Limited celebrates four decades with a robust 9% rise in net profit and a strategic digital transformation, positioning itself at the forefront of Australia’s retirement income market.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.